Navigation Links
NOV in Biological Technology

Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO

...S EST), Level 2, West Hall C. The poster entitled " P h ase I e val u ation of orally-ad m inistered CYT997, a nov e l cytotoxic vascular- d isrupting agent, in patients with advanced cance r " details safety, tolerability and pre...

YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER

...onths, which compares very favorably with historical data (Brundage Can J Oncol. 1996 Feb; 6 Suppl 1:25-32.; Bezjak Int J Radiat Oncol Biol Phys. 2002 nov 1;54(3):719-28; Sundstrom J Clin Oncol. 2004 Mar 1;22(5):801-10). "Numerous NSCLC patients undergo radiotherapy because they are unfit for radical c...

/C O R R E C T I O N -- Rosetta Genomics Ltd/

... In the news release, "Rosetta Genomics to Present at Rodman & Renshaw 10th Annual Healthcare Conference" issued on 5 nov 2008 13:30 GMT, by Rosetta Genomics Ltd nasdaq:ROSG over PR Newswire, we are advised by a representative of the company that new webcast information h...

European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia

...uloxetine 60-120 mg Versus Placebo in the Treatment of Fibromyalgia Syndrome. Poster presented at the American College of Rheumatology Annual Meeting; nov 2007, Boston, MA. (5) Chappell, AS, et al. A 1-Year Safety and Efficacy Study of Duloxetine in Patients with Fibromyalgia. Poster presented at Europ...

Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery

...clinic/ta/gist/gist1.htm 7. Gleevec(R) (imatinib mesylate) tablets prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; nov 2007. Media Contacts Media only: Kim Fox, Novartis Oncology, P: +1 862 778 7692 Dana Kahn Cooper, P: +1 732 817 1800, C: +1 732 239 6664 Inve...

Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia

...udy. Blood, Feb 2008. 3. Gleevec(R) (imatinib mesylate) tablets prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; nov 2007. Media Contacts Media Only: Kim Fox Novartis Oncology P: +1 862 778 7692 C: +1 917 415 2425 Dana Kahn Cooper P: +1 732 817 1800 C: +1...

FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults

..., Education and Welfare, 1976 9. "Introduction," Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder. NIH Consensus Statement 1998 nov 16-18; 16(2): 1-37. Available at: http://consensus.nih.gov/1998/1998AttentionDeficitHyperactivityDisorder11 0html.htm Accessed on May 7, 2007 (...

FDA Accepts Ranexa(R) sNDA and NDA for Filing

... PALO ALTO, Calif., nov 19 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) announced today that the U.S. Food and Drug Administration (FDA) has notified the ...

BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet

...://www.signplus.com/company Contact: Softpro GmbH, Joerg-M. Lenz, jle@softpro.de , Mobile: +49-160-4788-512, at the show in Las Vegas from nov 13 - 15 Wilhelmstrasse 34, 71034 Boeblingen, Germany ...

Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales

...is as follows: 2007 Financial Guidance as of as of as of (dollars in millions) Jan 4, 2007 Jul 26, 2007 nov 1, 2007 VELCADE U.S. net sales $240 - 260 $250 - 260 $~265 Royalties $140 - 150 $150 - 155 $~160 ...

Oragene is compatible with TaqMan SNP genotyping

... Trends Genet. 14, 266272. 3. Technical Bulletin: DNA Quantification Using the Fluorescence/DNase (F/D) Assay, v1.2. DNA Genotek. nov 29, 2004. 4. TaqMan SNP Genotyping Assays Protocol. Part Number 4332856 Rev. B. Applied Biosystems. June, 2004. back...

Oragene and Whole Genome Amplification with GenomiPhi

... Biotech. 21(12): 531-535. 2. Technical Bulletin: DNA Quantification Using the Fluorescence/DNase (F/D) Assay, v1.2. DNA Genotek. nov 29, 2004. 3. TaqMan SNP Genotyping Assays Protocol. Part Number 4332856 Rev. B. Applied Biosystems. June, 2004. 4. Tec...
Other Tags
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
(Date:4/17/2015)... Beverly Hills, California (PRWEB) April 17, 2015 ... Meier stands above in his new offering of platelet-rich ... Meier Orthopedic Sports Medicine (MOSM) is known for ... and Dr. Meier brings extensive surgical experience lacking in ... PRP and stem cell treatments are utilized for pain ...
(Date:4/17/2015)... April 17, 2015 Most dental patients ... restoration units are made overseas by foreign dental laboratories, ... labs remain unregulated in more than 40 states by ... National Association of Dental Laboratories has created the ... awareness among patients about the consequences that could be ...
(Date:4/17/2015)... 2015 Baptist Health and The University ... partnership agreement designed to transform oncology care in northeast ... agreed to create a joint cancer program to enhance ... research. Baptist MD Anderson Cancer Center is anticipated to ... destination for highly coordinated, multidisciplinary cancer care for adults ...
(Date:4/17/2015)... 17, 2015 Scientists from the ... team of U.S. and Venezuelan researchers, have discovered ... humans among an isolated tribe of Yanomami Amerindians ... diversity in the Yanomami, previously unexposed to antibiotics ... double that of people living in industrialized countries, ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Connie Casad, ... and functional medicine advocate with 30 years of practice ... be adding another level of service for her patients ... website of 10 recommended wellness books with a brief ... asked to explain her interest in providing this service, ...
Breaking Medicine News(10 mins):Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:National Association Urges Transparency in Dental Industry 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3Health News:Connie Casad, M.D. Provides Patients Recommended List of Wellness Books on Website 2
Other Contents